Nov 06, 2018
Rigel Announces Third Quarter 2018 Financial Results and Provides Company Update
Oct 30, 2018
Rigel Announces Conference Call and Webcast to Report Third Quarter 2018 Financial Results
Oct 29, 2018
Rigel Pharmaceuticals Enters Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. to Develop and Commercialize TAVALISSE(TM) (fostamatinib disodium hexahydrate) in Japan and other Asian Countries
Sep 27, 2018
Rigel to Host Investor & Analyst Day in New York City on October 4, 2018
Sep 24, 2018
Rigel to Present at the Cantor Global Healthcare Conference
Aug 29, 2018
Rigel to Present at the 20th Annual Global Investment Conference in New York City
Aug 08, 2018
Rigel Announces Second Quarter 2018 Financial Results and Provides Company Update
Jun 20, 2018
Rigel Announces Poster Presentations at FOCIS Annual Meeting
May 31, 2018
Rigel to Present at Jefferies 2018 Global Healthcare Conference
May 30, 2018
Rigel Appoints Dean Schorno as Chief Financial Officer
May 29, 2018
Rigel Announces Availability of TAVALISSE(TM) (fostamatinib disodium hexahydrate) in the U.S.
Apr 24, 2018
Rigel Announces Conference Call and Webcast to Report First Quarter 2018 Financial Results
Apr 12, 2018
Rigel Makes Statement Regarding Website Error
Feb 27, 2018
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2017 Financial Results
Feb 16, 2018
Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Jan 26, 2018
Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Jan 05, 2018
Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Dec 15, 2017
Rigel Announces Departure of Chief Financial Officer
Dec 08, 2017
Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Nov 17, 2017
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)